Peritoneal (Abdominal Mesothelioma)
Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years
Virchows Archive 2023 July 10 [Link] Nikola Vitlarov, E Burtscher, E Pfeiffenberger, A Wahl, V Hodja, Z Jasarevic, K Kashofer, F A Offner Abstract Papillary mesothelioma in situ (PMIS) is a rare and enigmatic disease. Most instances manifest as lesions of the peritoneal serosa. The pathogenesis and behavior of peritoneal PMIS are still poorly understood,…
Read MoreGenetic Pathways in Peritoneal Mesothelioma Tumorigenesis
Cancer Genomics and Proteomics 2023 Jul-Aug [Link] Ioannis Panagopoulos, Kristin Andersen, Marta Brunetti, Ludmila Gorunova, Ben Davidson, Marius Lund-Iversen, Francesca Micci, Sverre Heim Abstract Background/aim: Mesotheliomas are tumors similar to, and probably derived from, mesothelial cells. They carry acquired chromosomal rearrangements, deletions affecting CDKN2A, pathogenetic polymorphisms in NF2, and fusion genes which often contain the…
Read MoreHigh-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?
Indian Journal of Surgical Oncology 2023 June [Link] Praveen Kammar, Niharika Garach, Aditi Bhatt, Jay Anam, Vashisth Maniar, Adwaita Gore, Sanket Mehta Abstract Objective: To evaluate the feasibility, tolerance, and efficacy of OMCT (oral metronomic chemotherapy) after CRS + HIPEC for peritoneal mesothelioma in patients with poor prognostic factors: PCI > 20, incomplete CRS, poor…
Read MoreSynchronous Pleural and Peritoneal Mesothelioma: a Case Report and Narrative Review
Indian Journal of Surgical Oncology 2023 June [Link] Miguel Enrique Alberto Vilchez, Eva Pachmayr, Alexander Arnold, Safak Gül-Klein, Andreas Brandl, Beate Rau Abstract Malignant mesotheliomas most often affect the pleura and tend to spread locally within the originating cavity. Mesotheliomas are already rare diseases, and cases with synchronous pleural and peritoneal involvement are scarce in…
Read MoreHigh-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?
Indian Journal of Surgical Oncology 2023 June [Link] Praveen Kammar, Niharika Garach, Aditi Bhatt, Jay Anam, Vashisth Maniar, Adwaita Gore, Sanket Mehta Abstract Objective: To evaluate the feasibility, tolerance, and efficacy of OMCT (oral metronomic chemotherapy) after CRS + HIPEC for peritoneal mesothelioma in patients with poor prognostic factors: PCI > 20, incomplete CRS, poor…
Read MoreEstablishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
International Journal of Hyperthermia 2023 [Link] Yan-Dong Su, Xin Zhao, Ru Ma, Yu-Bin Fu, Zhi-Ran Yang, He-Liang Wu, Yang Yu, Rui Yang, Xin-Li Liang, Xue-Mei Du, Yue Chen, Yan Li Abstract Objectives: To establish a Bayesian network (BN) model to predict the survival of patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS)…
Read MorePressurized intraperitoneal aerosol chemotherapy, reasons for interrupting treatment: a systematic review of the literature
Pleura and Peritoneum 2023 April 19 [Link] Anne-Cecile Ezanno, Brice Malgras, Marc Pocard Abstract Objectives: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) gives encouraging results in the treatment of peritoneal metastasis (PM). The current recommendations require at least 3 sessions of PIPAC. However, some patients do not complete the full treatment course and stop after only 1…
Read MoreCytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes
Journal of Surgical Oncology 2023 May 30 [Link] Melina Deban, Kadhim Taqi, Gregory C Knapp, Mikael Soucisse, Matt Curry, Lucas Sidéris, Pierre Dubé, Maher Al Khaldi, Nicole Jedrzejko, Geoff Porter, Carman Giacomantonio, Trevor Hamilton, Andrea MacNeill, Lloyd Mack, Antoine Bouchard-Fortier Abstract Introduction: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive…
Read MoreThe clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma
Annals of Diagnostic Pathology 2023 August [Link] Xuemei Du, Xinbao Li, Bingdong Zhang, Zechen Hao, Ying Gao, Xi Jiang, Zhiran Yang, Yizhi Chen Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. TOP2A expression is associated with cell proliferation and cell cycle progression. We…
Read MoreMetabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
International Journal of Molecular Sciences 2023 April 24 [Link] Marika A Franczak, Oliwia Krol, Gabriela Harasim, Agata Jedrzejewska, Nadia Zaffaroni, Carlotta Granchi, Filippo Minutolo, Amir Avan, Elisa Giovannetti, Ryszard T Smolenski, Godefridus J Peters Abstract Malignant mesothelioma (MM) is a highly aggressive and resistant tumor. The prognostic role of key effectors of glycolytic metabolism in…
Read More